Berberine inhibits PTP1B activity and mimics insulin action

Biochemical and Biophysical Research Communications

Volumn 397, Issue 3, 2010, Pages 543-547

  Chen, Chunhua ^a   Zhang, Yuebo ^b   Huang, Cheng ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

3T3 L1; Berberine; Diabetes; Insulin; Insulin receptor substrates; Protein tyrosine phosphatase 1B

Indexed keywords

BERBERINE; INSULIN; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE 1B; ROSIGLITAZONE;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GLUCOSE TRANSPORT; HEART MUSCLE CELL; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SYNTHESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; BERBERINE; DIET; FEMALE; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MICE; MICE, INBRED C57BL; MUSCLE CELLS; OBESITY; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1;

MUS;

EID: 77954214500     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.05.153     Document Type: Article

References (27)

1. Goodyear L.J., Giorgino F., Sherman L.A., Carey J., Smith R.J., Dohm G.L. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J. Clin. Invest. 1995, 95:2195-2204.
2. Ahmad F., Azevedo J.L., Cortright R., Dohm G.L., Goldstein B.J. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J. Clin. Invest. 1997, 100:449-458.
3. Ramachandran C., Aebersold R., Tonks N.K., Pot D.A. Sequential dephosphorylation of a multiply phosphorylated insulin receptor peptide by protein tyrosine phosphatases. Biochemistry 1992, 31:4232-4238.
4. Zhang B., Salituro G., Szalkowski D., Li Z., Zhang Y., Royo I., Vilella D., Diez M.T., Pelaez F., Ruby C., Kendall R.L., Mao X., Griffin P., Calaycay J., Zierath J.R., Heck J.V., Smith R.G., Moller D.E. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 1999, 284:974-977.
5. Manchem V.P., Goldfine I.D., Kohanski R.A., Cristobal C.P., Lum R.T., Schow S.R., Shi S., Spevak W.R., Laborde E., Toavs D.K., Villar H.O., Wick M.M., Kozlowski M.R. A novel small molecule that directly sensitizes the insulin receptor in vitro and in vivo. Diabetes 2001, 50:824-830.
6. Kamerlin S.C., Rucker R., Boresch S. A molecular dynamics study of WPD-loop flexibility in PTP1B. Biochem. Biophys. Res. Commun. 2007, 356:1011-1016.
7. Kong W., Wei J., Abidi P., Lin M., Inaba S., Li C., Wang Y., Wang Z., Si S., Pan H., Wang S., Wu J., Wang Y., Li Z., Liu J., Jiang J.D. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 2004, 10:1344-1351.
8. Wang Y.X., Wang Y.P., Zhang H., Kong W.J., Li Y.H., Liu F., Gao R.M., Liu T., Jiang J.D., Song D.Q. Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor. Bioorg. Med. Chem. Lett. 2009, 19:6004-6008.
9. Leng S.H., Lu F.E., Xu L.J. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol. Sin. 2004, 25:496-502.
10. Lee Y.S., Kim W.S., Kim K.H., Yoon M.J., Cho H.J., Shen Y., Ye J.M., Lee C.H., Oh W.K., Kim C.T., Hohnen-Behrens C., Gosby A., Kraegen E.W., James D.E., Kim J.B. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55:2256-2264.
11. Zhang H., Wei J., Xue R., Wu J.D., Zhao W., Wang Z.Z., Wang S.K., Zhou Z.X., Song D.Q., Wang Y.M., Pan H.N., Kong W.J., Jiang J.D. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 2010, 59:285-292.
12. Zhang Y., Li X., Zou D., Liu W., Yang J., Zhu N., Huo L., Wang M., Hong J., Wu P., Ren G., Ning G. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J. Clin. Endocrinol. Metab. 2008, 93:2559-2565.
13. Tang L.Q., Wei W., Chen L.M., Liu S. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J. Ethnopharmacol. 2006, 108:109-115.
14. Huang C., Zhang Y., Gong Z., Sheng X., Li Z., Zhang W., Qin Y. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway. Biochem. Biophys. Res. Commun. 2006, 348:571-578.
15. Tanishita T., Shimizu Y., Minokoshi Y., Shimazu T. The beta3-adrenergic agonist BRL37344 increases glucose transport into L6 myocytes through a mechanism different from that of insulin. J. Biochem. (Tokyo) 1997, 122:90-95.
16. Sweeney G., Keen J., Somwar R., Konrad D., Garg R., Klip A. High leptin levels acutely inhibit insulin-stimulated glucose uptake without affecting glucose transporter 4 translocation in l6 rat skeletal muscle cells. Endocrinology 2001, 142:4806-4812.
17. Harrity T., Farrelly D., Tieman A., Chu C., Kunselman L., Gu L., Ponticiello R., Cap M., Qu F., Shao C., Wang W., Zhang H., Fenderson W., Chen S., Devasthale P., Jeon Y., Seethala R., Yang W.P., Ren J., Zhou M., Ryono D., Biller S., Mookhtiar K.A., Wetterau J., Gregg R., Cheng P.T., Hariharan N. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. Diabetes 2006, 55:240-248.
18. Ko B.S., Choi S.B., Park S.K., Jang J.S., Kim Y.E., Park S. Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma. Biol. Pharm. Bull. 2005, 28:1431-1437.
19. Chen H., Charlat O., Tartaglia L.A., Woolf E.A., Weng X., Ellis S.J., Lakey N.D., Culpepper J., Moore K.J., Breitbart R.E., Duyk G.M., Tepper R.I., Morgenstern J.P. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996, 84:491-495.
20. Kodama H., Fujita M., Yamaguchi I. Development of hyperglycaemia and insulin resistance in conscious genetically diabetic (C57BL/KsJ-db/db) mice. Diabetologia 1994, 37:739-744.
21. Chang L., Chiang S.H., Saltiel A.R. Insulin signaling and the regulation of glucose transport. Mol. Med. 2004, 10:65-71.
22. Schinner S., Scherbaum W.A., Bornstein S.R., Barthel A. Molecular mechanisms of insulin resistance. Diabet. Med. 2005, 22:674-682.
23. Bustanji Y., Taha M.O., Yousef A.M., Al-Bakri A.G. Berberine potently inhibits protein tyrosine phosphatase 1B: investigation by docking simulation and experimental validation. J. Enzyme Inhib. Med. Chem. 2006, 21:163-171.
24. Tang Q.Q., Otto T.C., Lane M.D. Mitotic clonal expansion: a synchronous process required for adipogenesis. Proc. Natl. Acad. Sci. USA 2003, 100:44-49.
25. Winzell M.S., Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 2004, 53(Suppl. 3):S215-S219.
26. Fajans S.S., Brown M.B. Administration of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young. Diabet. Care 1993, 16:1254-1261.
27. Panten U., Burgfeld J., Goerke F., Rennicke M., Schwanstecher M., Wallasch A., Zunkler B.J., Lenzen S. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets. Biochem. Pharmacol. 1989, 38:1217-1229.